All In Biotech

Drug Trial Radar · NCT00435279

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia

Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 678 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

678

Actual

Start

Jun 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).

Conditions

  • Major Depressive Disorder
  • Insomnia

Interventions

  • EszopicloneDrug

    Eszopiclone 3 mg

  • PlaceboDrug

    Placebo

  • VenlafaxineDrug

    Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.Time frame: Week 8

Locations

69 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Split, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Arcachon, France

  • Site not named

    Caen, France

  • Site not named

    Élancourt, France

  • Site not named

    Le Pecq, France

  • Site not named

    Rennes, France

  • Site not named

    Savigny-sur-Orge, France

  • Site not named

    Strasbourg, France

  • Site not named

    Toulouse, France

  • Site not named

    Toulouse, France

  • Site not named

    Toulouse, France

  • Site not named

    Verasailles, France

  • Site not named

    Balassagyarmat, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Cegléd, Hungary

  • Site not named

    Nyíregyháza, Hungary

  • Site not named

    Bełchatów, Poland

  • Site not named

    Bydgoszcz, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Torun, Poland

  • Site not named

    Tuszyn, Poland

  • Site not named

    Bucharest, Romania

  • Site not named

    Lasi, Romania

  • Site not named

    Oradea, Romania

  • Site not named

    Arkhangelsk, Russia

  • Site not named

    Belchatow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.